Literature DB >> 35089363

[What should specialist in internal medicine be aware of in patients treated with biologics? : Infections and autoimmune phenomena].

Thomas Zander1, Michael Hallek2.   

Abstract

Biologics that influence the immune system play a crucial role in the treatment of autoimmune and malignant diseases. Overall these drugs have revolutionized treatment as they demonstrate high efficacy and a relatively low amount of side effects. This leads to longer treatment of patients with a high quality of life. Side effects, especially longer-term side effects, become ever more important as patients are simultaneously seen by different physicians due to comorbidities. Infections, mainly of the upper airway or urogenital tract, represent the main side effect of immunosuppressive biologics, but atypical infections by fungi or mycobacteria may also occur. Biologics that enhance the immune response such as checkpoint inhibitors lead to autoimmune phenomena necessitating the interruption of treatment or immunosuppressive treatment.
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Biologicals/adverse effects; Immune checkpoint inhibitors; Immunomodulating agents; Immunosuppressive agents; Infection risk

Mesh:

Substances:

Year:  2022        PMID: 35089363     DOI: 10.1007/s00108-021-01259-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  36 in total

1.  Nivolumab in previously untreated melanoma without BRAF mutation.

Authors:  Caroline Robert; Georgina V Long; Benjamin Brady; Caroline Dutriaux; Michele Maio; Laurent Mortier; Jessica C Hassel; Piotr Rutkowski; Catriona McNeil; Ewa Kalinka-Warzocha; Kerry J Savage; Micaela M Hernberg; Celeste Lebbé; Julie Charles; Catalin Mihalcioiu; Vanna Chiarion-Sileni; Cornelia Mauch; Francesco Cognetti; Ana Arance; Henrik Schmidt; Dirk Schadendorf; Helen Gogas; Lotta Lundgren-Eriksson; Christine Horak; Brian Sharkey; Ian M Waxman; Victoria Atkinson; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.

Authors:  Gert J D Bergman; Marc C Hochberg; Maarten Boers; Neil Wintfeld; Adrian Kielhorn; Jeroen P Jansen
Journal:  Semin Arthritis Rheum       Date:  2010-03-11       Impact factor: 5.532

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

Review 5.  Role of abatacept in the management of rheumatoid arthritis.

Authors:  Anna Nogid; David Q Pham
Journal:  Clin Ther       Date:  2006-11       Impact factor: 3.393

Review 6.  The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors.

Authors:  R Demlova; D Valík; R Obermannova; L ZdraŽilová-Dubská
Journal:  Physiol Res       Date:  2016-12-21       Impact factor: 1.881

7.  Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.

Authors:  Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Juliane Gust; W Conrad Liles; Mark M Wurfel; José A López; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Sindhu Cherian; Xueyan Chen; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2017-09-18       Impact factor: 22.113

8.  Pembrolizumab versus Ipilimumab in Advanced Melanoma.

Authors:  Caroline Robert; Jacob Schachter; Georgina V Long; Ana Arance; Jean Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona McNeil; Michal Lotem; James Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Omid Hamid; Christine Mateus; Ronnie Shapira-Frommer; Michele Kosh; Honghong Zhou; Nageatte Ibrahim; Scot Ebbinghaus; Antoni Ribas
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

Review 9.  ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).

Authors:  K L Winthrop; X Mariette; J T Silva; E Benamu; L H Calabrese; A Dumusc; J S Smolen; J M Aguado; M Fernández-Ruiz
Journal:  Clin Microbiol Infect       Date:  2018-02-12       Impact factor: 8.067

10.  Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial.

Authors:  Peter C Taylor; Emilia Quattrocchi; Stephen Mallett; Regina Kurrasch; Jørgen Petersen; David J Chang
Journal:  Ann Rheum Dis       Date:  2011-08-22       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.